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Ontogenesis of oxytocin (OT) and vasopressin (VP) gene expression and function were investigated in murine thymus. OT and VP
transcripts were detected in the thymus on embryonic days 13 and 15, respectively. Corresponding messenger RNAs were evidenced in
thymic epithelial cells by in situ hybridization with a neurophysin probe. From all OT and VP receptors, only OTR was expressed by all T-
cell subsets, while V1bR was found in double positive and single positive CD8 cells. In fetal thymic organ cultures, OTR antagonist d[d-
Tyr(Et)2, Thr4]OVT increased early apoptosis of CD8 cells, while V1bR antagonist (Sanofi SSR149415) inhibited T-cell differentiation, and
favored CD8 T-cell commitment.
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The thymus exerts a fundamental role both in the
establishment of T-cell self-tolerance by deletion of self-
reactive T cell clones and generation of self-antigen specific
CD4+CD25+ regulatory T cells, as well as in the develop-
ment of major histocompatibility complex (MHC)-restricted
competent and self-tolerant T cells (thymopoiesis) (Geenen
et al., in press). An important factor leading to T-cell death
or development is the density of the natural ligands (peptide/
MHC complexes) expressed in the thymus and presented to
pre-T cells (Ashton-Rickardt et al., 1994; Sebzda et al.,
1999). Stochastic recombination of T-cell antigen receptor
(TCR) chain genes generates a repertoire of TCR potentially
reactive to a wide spectrum of self-antigens. Cells that
express a TCR unable to recognize any self-peptide/MHC0165-5728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.jneuroim.2004.08.007
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1 Both authors contributed equally to this work.complexes die by neglect. T-cell clonal deletion results from
high-affinity TCR ligation to self-peptide/MHC complexes
at high density (negative selection). On the contrary, TCR
recognition of self-peptide/MHC complexes at low density,
or a high density of low affinity interactions, mediates T-cell
positive selection.
Our understanding of thymic physiology highly pro-
gressed with the demonstration that thymic stromal cells
transcribe a repertoire of neuroendocrine-related and other
peripheral tissue antigen-encoding genes (Geenen et al.,
1995; Kyewski et al., 2002). Thymic neuroendocrine
precursors play a dual role in T-cell selection according to
their processing either as self-antigens for T-cell negative
selection, or as accessory ligands for the development of
self-tolerant T cells (Martens et al., 1996a). The repertoire of
thymic neuroendocrine precursors expressed is organized in
such a way that one dominant member per family is
expressed in the thymus. Thymic neuroendocrine self-
antigens usually correspond to sequences highly conserved
throughout evolution of one given family: oxytocin (OT) vs.gy 158 (2005) 67–75
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neurokinin A vs. substance P for tachykinins (Ericsson et
al., 1990), and insulin-like growth factor 2 (IGF-2) vs. IGF-
1 and proinsulin for the insulin family (Geenen et al., 1993;
Martens et al., 1996a).
Hypothalamic magnocellular neurons are the major site
of OT and VP expression (for a complete review, see
Gainer and Wray, 1993). These genes encode 16- and 20-
kDa precursors, respectively, that are processed during
their axonal transport towards neurohypophysis into active
nonapeptides OT and VP, and their specific carriers 10-
kDa neurophysins. Though they only differ by two amino
acids, the physiological actions of these two peptides are
completely different. After binding to a specific receptor
(OTR), OT triggers milk ejection and intervenes in the
contractility of uterine myometrium during parturition. VP
inhibits water diuresis through kidney VP type 2
receptors (V2R), contributes to the regulation of vascular
tone through V1a receptors (V1aR), and stimulates
secretion of adrenocorticotropin (ACTH) through V1b
receptors (V1bR). As a source of hypothalamus-specific
antigens, OT and VP are also expressed in TEC from
different species, although with a dominance of OT at the
peptide level. Thymic OT is not secreted but targeted to
the outer surface of TEC plasma membrane where it is
recognized by specific monoclonal antibodies (mAbs)
(Martens et al., 1996b). Specific and functional receptors
for these peptides are expressed by human thymocytes
and a murine double negative (DN) CD4CD8 pre-T
cell line RL12-NP (Martens et al., 1992). After binding to
their cognate receptors, OT and VP act as mitogenic
signals through activation of the phosphoinositide path-
way in T cells (Elands et al., 1990; Martens et al., 1992).
In addition, a rapid phosphorylation of p125FAK in
murine pre-T cells follows their treatment with OT and
VP, in particular with OT (Martens et al., 1998). Thus,
thymic OT constitutes an early activation signal for
immature T cells and promotes focal adhesions to TEC
during their early differentiation in the thymus. However,
the precise nature of the receptors expressed by T-cell
subsets remains undefined, and previous studies have
suggested that more than one receptor could be impli-
cated (Martens et al., 1992; Torres and Johnson, 1988).
The identification of those receptors based on trans-
duction mechanisms and biochemical events is further
intricate by the fact that some of these receptors poorly
discriminate their ligands. For example, OT drives ACTH
release from rat pituitary after binding to V1bR
(Schlosser et al., 1994).
The main objectives of this study were to compare the
ontogenesis of OT and VP expression in murine brain and
thymus, to determine the distribution of OTR, V1aR,
V1bR and V2R in murine thymic T cell subsets, as well
as to investigate the effects of the blockade of OT- and
VP-mediated signaling upon T-cell differentiation and
apoptosis.2. Materials and methods
2.1. Cells and tissue collection
Balb/c and C57BL6/Ka mice were mated overnight.
Plugged females were considered as positive and separated
in the morning of the so-called embryonic day 0 (E0).
Matched thymi and brains were collected from E13 to E20,
and on post-natal day 2. Thymi were used for fetal thymic
organ cultures (FTOC), as described by Plum et al. (1995),
for total RNA extraction, or were embedded in OCT
(Sakura, Torrance, CA) for in situ hybridization. The
experimental procedures were carried out in accordance
with the Ethical Committee on Animal Experimentation at
the University of Liege.
FTOC were grown for 7 days in 1-ml medium (IMDM,
penicillin 50 IU/ml, streptomycin 50 ng/ml, FCS 10%, l-
Glutamine 2 mM, NEAA 1%, HEPES, 1%, Na Pyruvate
1%) (Cambrex) in basal conditions or in presence of d[d-
Tyr(Et)2, Thr4]OVT (Atosiban), a specific OTR antagonist
(1 AM) kindly provided by Maurice Manning (Medical
College of Ohio, Toledo) (Manning et al., 1995), and SSR
149415, a specific V1b antagonist (1 AM) from Sanofi-
Synthelabo (Montpellier, France) (Serradeil-Le Gal et al.,
2002). Control cultures were performed in basal medium, or
added with 0.002% DMSO. For the analysis of antagonist
effects, medium was supplemented each day of the culture
with a 20 Al of 50-fold concentrated tested antagonist
solutions and with 0.002% DMSO for matched controls.
The type of receptor expressed by thymic T cell
subpopulations was analyzed from thymic lobes surgically
removed from 8-week-old female C57BL6/Ka mice. They
were cut in small pieces, filtered and washed in DPBS
buffer. After three successive incubations (15 min, 4 8C),
thymocyte suspension was incubated with a mAb cocktail
prepared for negative selection of CD4 and CD8 T cells
(StemCell Technologies). DN cells were obtained by
combination of procedures. DP cells were N90% in the
crude suspension. After washing in DPBS buffer, an anti-
biotin tetrameric Ab complex mix (StemCell Technologies)
was added. The last incubation was performed with a
magnetic colloid (StemCell Technologies). Separation was
realized with a MACS column (Miltenyi Biotec). This pre-
purification step (from 70% to 80% purity) allows a FACS
sampling of highly purified DN, DP, CD4+ and CD8+
subpopulations (N95%).
2.2. RNA preparation, cDNA synthesis and PCR
amplification
Total RNA from 4-week-old mice hypothalamus was
used as positive control for OT and VP expression. RT-PCR
was performed using Ready-to-Go beads (Amersham-
Pharmacia Biotech, The Netherlands). Fifty nanograms of
total RNA extracted with RNeasy Mini Kit (Qiagen),











































































































































































































































































































































































































































































































































































































































































































































































































































I. Hansenne et al. / Journal of Neuroimmunology 158 (2005) 67–75 69were transcribed in cDNA 30 min at 42 8C with random
hexamers, denatured at 94 8C for 5 min and amplified by
35 PCR cycles of 45 s at 94 8C; 45 s at 66 8C, 90 s at 72
8C and a final 10-min extension at 72 8C with 10 pmol of
specific OT and VP primers (Table 1). To ensure mRNA
quality and similar loading in each sample, h-actin mRNA
was amplified in the same conditions, except that anneal-
ing temperature was 54 8C (Pleau et al., 1996). Alter-
natively, OT and VP nested-PCR was performed with 1:20
dilution of RT-products from 250 ng total RNA transcribed
with AMV (Roche, Belgium), followed by 35 PCR cycles
with OT* and VP* primers (Table 1, annealing temper-
ature=62 and 64 8C, respectively) and a second step of 35-
cycles PCR with OT and VP primers and 1:5000 dilution
of first step products, both with 2 IU of FastStart Taq
polymerase (Roche). RT-PCR products were subcloned in
pCR2.1-TOPO plasmid (Invitrogen) and sequenced using
ABI Prism BigDye Terminator Cycle Sequencing Ready
Reaction Kit protocol (Perkin Elmer) to ensure OT and VP
identity.
OT and VP expression in the thymus during FTOC was
investigated by RT-PCR followed by Southern blotting. The
amplified RT-PCR products were separated by 2% gel
agarose, transferred on membrane (GeneScreen-Plus, NEN,
Belgium), and hybridized with the corresponding internal
oligonucleotide probes. Oligonucleotides (50 ng) were
labeled with [g 32P] dATP (5 Al, 4500 Ci/mmol) using T4
kinase (7.9 IU) (Pharmacia), then purified on BIO-RAD
Micro Bio-spin Column P-30 Tris, RNase-Free. Gene
Screen Plus membranes were prehybridized (2 h, 60 8C)
in SSC (5), Na3PO4 (20 mM), Denhardt solution (50),
SDS (7%) and salmon sperm DNA (0.1 ng/ml). This was
followed by hybridization (12 h, 60 8C) in prehybridization
solution+dextran sulfate (20%) with labeled OT (c106
cpm/ml) or VP (c106 cpm/ml) probe. Membranes were
washed in SSC (5) (30 min, 60 8C) and in SSC (2) (30
min, 60 8C). Autoradiographies were developed after a 2-
day exposure at 70 8C.
For receptor analyses, positive controls were RNA from
adult mice uterus (OTR), liver (V1aR), kidney (V2R) and
anterior pituitary (V1bR). Milli-Q quality water was used as
negative control. Total RNA from murine uterus, liver,
kidney and anterior pituitary was extracted with TriPure
Isolation Reagent (Boerhinger Mannheim). Total RNA from
purified thymocytes subsets was extracted with RNeasy
Mini Kit (Qiagen). All were treated (15 min, 37 8C) with
DNase I. RNA was quantified with Ribogreen RNA
Quantitation Kit (Molecular Probes). Primers were designed
from murine OTR, V1aR, V2R, V1bR, sequences (Table 1)
and selected in different exons in order to exclude genomic
DNA from amplification. Total RNA (50 ng) of each sample
was reverse-transcribed with random hexamers (30 min, 42
8C). After denaturation (5 min, 94 8C), the samples were
submitted to PCR with 35 cycles (for OTR, V1aR and V2R),
or with 37 cycles (for V1bR). For each cycle, denaturation
was 94 8C for 1 min (OTR, V1aR, V2R and V1bR),
I. Hansenne et al. / Journal of Neuroimmunology 158 (2005) 67–7570hybridization was 1 min at 56 8C (OTR, V1aR and V2R) and
64 8C (V1bR), elongation was 1 min (OTR, V1aR, V2R,
V1bR) at 72 8C and a final 10-min extension at 72 8C. h-
actin mRNAwas amplified in the same conditions, excepted
that annealing temperature was 54 8C. RT-PCR products
were analyzed on 2% agarose gel with ethidium bromide.
RT-PCR products were subcloned in pCR2.1-TOPO plas-
mid (Invitrogen) and sequenced using ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit protocol
(Perkin Elmer). Southern blotting was performed to ensure
the specificity of the products. Receptor RT-PCR products
were transferred on Hybond-XL membrane (Amersham
Pharmacia Biotech). Oligonucleotide probes were synthe-
sized in the internal sequence of the amplified products
(Table 1) and labeled as described. Hybond XL membranes
were prehybridized (2 h at 65 8C) in Denhardt solution
(5), SSC (5) and SDS (0.5%) followed by hybridization
(12 h, 65 8C) in the same solution with labeled probe (c106
cpm/ml). Membranes were successively washed in a SSC
solution (2) and SDS (0.1%) (5 min), SSC (1) and SDS
(0.1%) (15 min), SSC (0.1) and SDS (0.1%) (10 min).
cDNAwas visualized with PhosphorImager after exposition
(2 h) or by autoradiography (70 8C, 2-day exposition).
2.3. In situ hybridization
The probe derived from the complete coding sequence of
human preprovasopressin (exon 2) cloned in the pGEM-3Z
plasmid and linearized with EcoRI and BamHI (Hara et al.,
1990; Rehbein et al., 1986). One microgram of sense and
antisense matrix riboprobes was synthesized, and 8-Am
tissue sections were fixed and stained as described (Kecha et
al., 2000).
2.4. Flow cytometry
After 7-day FTOC, cell suspensions were prepared and
5105 cells were stained for 20 min at 4 8C. Quadruple
staining was achieved with anti-CD4 coupled to phycoer-
ythrin (PE) (Biosciences Pharmingen, clone GK 1.5), and
anti-CD8 coupled to fluorescein isothiocyanate (FITC) Ab
(Biosciences Pharmingen, clone 53–6.7), annexin VFig. 1. RT-PCR amplification of OT, VP and OTR mRNA in murine thymi from E1
gel electrophoresis and visualized with ethidium bromide. The predicted sizes for
VP primers, 273 bp for OTR primers and 250 bp for Act (h-actin) primers. Thym
extracts on the right panel. MM=molecular markers EZ load, a=negative controlcoupled to APC (Biosciences Pharmingen); propidium
iodide (PI, Sigma) or 7-AAD (Biosciences Pharmingen)
was added prior to lecture. For each sample, events were
gated according to forward and side scatter profiles. Flow
cytometry was performed using a FACVantage Plus Cell
sorter (BD-Pharmingen) with a blue argon laser (488 nm)
and with CellQuest software. Fluorescence was determined
on 10,000 cells and stored in list mode data files.
2.5. Statistics
Results were expressed as meanFstandard deviation
(mFS.D.) of values after treatment vs. basal conditions.
Differences between groups were estimated by nonpara-
metric ANOVA Kruskal–Wallis test and analyzed by multi-
comparative Dunn’s test.3. Results
3.1. Ontogenesis of OT and VP transcription in Balb/c
brain and thymus
We have extracted total RNA from brain and thymi of
same mother’s fetuses in order to compare OT and VP
expression at the same age. By RT-PCR, OT transcripts
were detected in the thymus and in the brain from E13 to
post-natal day 2, while VP transcription was detected in the
brain on E14, started in the thymus on E14, but was clearly
observed on E15. A faint PCR product was detected on E13
with OT primers in one out of five brains and in five out of
five thymus. To check specificity of the transcripts, a nested
OT PCR was performed and revealed the presence of
transcripts in the brain on E13. Nested PCR allowed
detection of VP transcripts in the thymus and brain on
E14 (Fig. 1). OTR transcripts were detected from E13
thymus and brain to post-natal day 2 with a decrease in the
thymus and an increase in the brain after E17. Although
PCR conditions were not quantitative, these data never-
theless indicates that OT transcription in the thymus slightly
precedes or coincides the one observed in the central
nervous system (CNS).3–19 to post-natal day +2. RT-PCR products were separated by 2% agarose
the amplification bands using primer specific for OT are 211 bp, 188 bp for
ic total RNA extracts are presented on the left panel and brain total RNA
(H2O).
Fig. 2. RNA in situ hybridization of E18 murine thymus with neurophysin probe. Slices (magnification 200) were labeled with neurophysin antisense (A) and
sense (B) digoxigenin-labeled probe. Most of labeled cells are located in the subcapsular cortex (SCC) and in the medulla (arrows); a few positive cells are also
stained in the cortex, whereas methyl-green reveals a majority of T-cell nuclei in the cortex. Dashed lines delineate boundary between cortex and medulla in a
thymic lobule. Scale bar is 25 Am.
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In the fetal murine thymus, specific transcripts were
evidenced on E18 while no staining was detected with the
sense probe used as a negative control (Fig. 2). The use of
the neurophysin domain (exon 2) coding sequence allowed
to stain and to localize both OT and VP transcripts. A
staining of reticular cells was observed in the section. A
staining of a thin layer in the subcapsular cortex also
emerged from the background. The pattern of gene tran-
scription in the thymus was restricted to the epithelial
reticular network.
3.3. OT and VP receptor expression by thymic T-cell subsets
RT-PCR with V1aR and V2R primers revealed the
presence of 409- and 437-bp products in liver and kidney,
respectively, but failed to amplify any product in thymic T
cells (Fig. 3). Hybridization with specific probes confirmed
the absence of V1aR and V2R transcripts in all T cell
samples (data not shown). Note that V2R primers allow
amplification of genomic DNA at 593-bp in all samples andFig. 3. OT and VP receptor (OTR, V1aR, V1bR and V2R) expression in T-cell sub
MM: molecular mass marker; C: positive control; DN: double negative CD4CD
cells, CD8: single positive CD8+ cells. Arrows indicate the RNA amplified produa V2R short transcript (F300 bp) in positive control. RT-
PCR with OTR specific primers revealed the presence of a
273-bp product in the mouse uterus as positive control. A
same sized RT-PCR product was detected in all thymic T
cell subsets. Southern blotting of the PCR product and
hybridization with a specific probe confirmed the presence
of OTR transcripts in thymocytes (data shown). Sequencing
of the 237-bp T-cell product confirmed homology with
murine OTR sequence. RT-PCR with V1bR primers
identified a 254-bp product in mouse anterior pituitary as
positive control. A same sized product was similarly
detected in thymic DP and CD8+T cells, but never in DN
nor in CD4+. Southern blotting and hybridization with a
specific probe confirmed V1bR expression in DP and CD8+
thymic T cells (data not shown).
3.4. Fetal thymic organ cultures (FTOC)
RNA from thymic lobes was extracted at different days
of FTOC. Hybridization was performed after RT-PCR
amplification and southern blotting with specific OT and
VP probes. Both OT and VP transcriptions were maintainedsets. RT-PCR of total RNA from murine T cell subsets. a: negative control;
8 cells, DP: double positive CD4+CD8+ cells, CD4: single positive CD4+
cts for each receptor.
Fig. 4. FTOC control conditions. DN: double negative CD4CD8 cells, DP: double positive CD4+CD8+ cells, CD4+: single positive CD4+ cells, CD8+: single
positive CD8+ cells, V: viable cells, A: early apoptotic cells, T: terminal, late apoptotic cell, N: necrotic cells. Mean of all experiments is represented. D14 T-cell
subpopulations at the day of thymic sampling, n=8; d.21 T-cell subpopulations at the end of the culture in medium, n=14; d.21*: T-cell subpopulations at the
end of the culture in medium with control DMSO addition, n=16. Results are expressed as mean of the population percentage. Statistical significance of
differences was tested with nonparametric ANOVA Kruskal–Wallis followed by Dunn’s multi-comparative post-test.
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When FTOC were initiated, thymocytes were essentially
DN (N95%) with a small population of CD4low cells (F5%)
(Fig. 4). Very little apoptotic cells were numbered. After 7-
day culture, DN cells differentiated into four T-cell subsets:
DN (19.3%F3.00, mFS.D.); DP (53.4%F4.72); CD4+
(8.1%F1.93) and CD8+ (18.9%F2.85). Living cells were
82.2%F3.84, early apoptotic cells were 2.1%F2.06 and late
apoptotic cells were 4.4%F1.73. Vehicle control (DMSO/
medium, 1:50,000) only induced a nonsignificant increase
in the percentage of DN (23.17F2.02) and CD8+
(23.5F1.84) cells, as well as early and late apoptotic cells
(4.34F1.65 and 6.8F1.82, respectively) and decreased DP
cells (44.9F3.98).Fig. 5. Blockade of OTR and V1bR signaling during T-cell differentiation
in FTOC. Flow cytometry analyses show the percentage of T-lymphocyte
subpopulations stained either with anti-CD4, anti-CD8, Annexin-V and 7-
AAD, recovered from FTOC exposed to OTR antagonist or V1bR
antagonist for 1 week. Hundred percent are control conditions. DN:
CD4CD8 cells; DP: CD4+CD8+ cells; CD4+: single positive CD4+ cells;
CD8+: single positive CD8+ cells. Each column represents five experiments
in triplicate. Results are expressed as meanFstandard error of percentage
vs. reference values. Statistical significance was tested with nonparametric
ANOVA Kruskal–Wallis followed by Dunn’s multi-comparative post-test.
**pb0.01, ***pb0.001; Dunn’s test.The effects of specific receptor antagonists on T-cell
differentiation (Fig. 5) were investigated in FTOC. The
OTR antagonist Atosiban exerted a slight effect that,
however, was not significant. On the contrary, the V1bR
antagonist SSR149451 significantly increased DN and
CD8+ populations, and decreased DP cells. Significant
effects on cell viability were a decrease in early apoptosis of
the DN cells with the V1bR antagonist and an increase in
CD8+early apoptosis with the OTR antagonist (Table 2). No
significant effects were observed on total, DP and CD4+
cells viability parameters, and no difference appeared
between medium alone and controls (DMSO 1:50,000)
(data not shown).4. Discussion
Ontogenesis of OT and VP transcription in the murine
thymus has not been investigated so far. In the present study,
OT transcripts were detected by RT-PCR in the murine fetal
thymus as early as on E13, while VP transcription started onTable 2
Blockade of OTR and V1bR signaling on T-cell viability in FTOC
Basal* Atosiban SSR149451
DN/V 70.6F7.76 68.5F10.76 69.3F4.55
DN/A 3.5F1.19 6.6F3.80 3.0F2.63*
DN/T 8.6F3.13 12.7F8.09 8.9F4.19
DN/N 17.3F8.49 12.3F2.83 18.7F5.52
CD8/V 87.5F6.02 88.2F4.75 88.4F2.81
CD8/A 1.9F0.86 3.4F3.09* 1.6F1.06
CD8/T 4.8F1.97 5.5F2.27 4.7F2.00
CD8/N 5.9F4.84 2.9F1.24 5.3F2.68
V: viable cells; A: early apoptotic cells; T: terminal, late apoptotic cells; N:
Necrotic cells. DN: CD4CD8 cells; CD8+: single positive CD8+. Results
are expressed as mFS.D. of total population percentage. N=18. Statistical
significance was tested with nonparametric ANOVA Kruskal–Wallis
followed by Dunn’s multi-comparative post-test; Dunn’s test.
* pb0.05.
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thymic lobes could not be identified. By comparison, OT
transcription in the brain appeared on E13, while VP
expression was detected on E14. It must be pointed out
however that, only in 1 out of 5 experiments, OT
transcription could be detected in the brain on E13 without
nested PCR procedures. This unique result might be linked
to the imprecision of the plug date in relation to the exact
time of egg fertilization and embryonic development. The
expression of OT and VP in CNS has already been
investigated during murine ontogenesis. VP transcripts were
detected by in situ hybridization on E16 in the supraoptic
nucleus (SON), but were observable only on E21 (time of
birth) in the hypothalamic suprachiasmatic nucleus (SCN)
(Reppert and Uhl, 1987). A previous study has shown that
the OT precursor is detected in CNS as soon as on E16,
confirming the delay between fully processed VP and OT
(Whitnall et al., 1985). Thus, based on our observations and
the available literature, OT transcription in the thymus
precedes or more rarely coincides with that in the CNS.
Whereas preliminary assays with OT and VP oligonu-
cleotide probes failed to define a clear staining of thymic
sections, in situ hybridization with a neurophysin probe
(chosen in the conserved exon 2 of OT and VP) revealed
that fetal thymic reticular cells express OT and/or VP
transcripts. The cell feature, morphology, and overall
distribution correspond to TEC. This is in accordance with
our previous immunocytochemical studies showing that OT
and VP are identified in human and murine TEC, including
thymic nurse cells (TNC) (Geenen et al., 1988; Martens et
al., 1996b; Robert et al., 1991). OT and VP transcription in
the thymus is therefore coupled to mRNA translation and
precursor processing. A specific aspect of this peptide axis
in the thymus appears to be a peptide maturation that is
more precocious than in the hypothalamo-neurohypophysial
system during ontogenesis. In the rat CNS, OT prohormone
was not detected before E16, while the mature OT
nonapeptide appeared on E20–22 (Whitnall et al., 1985).
This difference in the delay of OT appearance in the thymus
and in the brain suggests a difference in the processing
between hypothalamic neurons and TEC. Such discrepancy
does not concern the late steps of OT processing since
peptidyl-glycine-a-amidating monooxygenase (PAM), the
last enzyme in the processing of neurohypophysial peptides
(Bradbury et al., 1982), is present in its active form in rat
thymic TEC (Martı´nez et al., 1998). It may be related to the
difference in the precursor processing in association with
neurohormone secretion in the hypothalamo-neurohypophy-
sial axis, and in association with self-antigen presentation in
the thymus during induction of central T-cell self-tolerance.
Supporting this hypothesis, it is very significant that fully
processed OT as the neurohypophysial self-antigen appears
in the central tolerogenic organ before or at least simulta-
neously with the one in CNS.
We previously showed that T-cell lines with an
immature CD4CD8 phenotype express functional recep-tors for OT and VP peptides (Martens et al., 1992). Among
all types of receptors (V1aR, V1bR, V2R and OTR), only
OTR transcripts were clearly evidenced in all thymus T-
cell subsets, while V1bR was detected in DP and CD8+
cells. Previous binding studies have also suggested V1bR
expression by immature T cells (Elands et al., 1990;
Martens et al., 1992; Torres and Johnson, 1988). Interest-
ingly, Northern blot analyses have detected the presence of
V1bR transcripts in rat thymus extracts (Lolait et al.,
1995), and recent data evidence OTR expression in
intralesional Kaposi’s sarcoma CD4+ and CD8+ T cells
(Cassoni et al., 2002). This last study suspected up-
regulation of OTR expression in the Kaposi’s sarcoma
environment, but we show here that it is detected in all
naive thymic T-cell subsets. We failed to detect any V1aR
transcripts in the T-cell subsets. This is in accordance with
a recent study using V1aR/ mice (Hu et al., 2003) that
shows the absence of effect of V1aR deletion upon thymic
T-cell differentiation, while it affects B-cell late differ-
entiation through modulation of B cell receptor. Taken
together, our data substantiate an active intrathymic
signaling mediated through OT/VP and OTR/V1b recep-
tors. In the thymus, OT is targeted to the outer surface of
human TEC plasma membrane from where it behaves
either as a self-antigen, or as a ligand for OTR expressed
by immature T cells. This latter interaction mediates
mitogenic effects in freshly isolated human thymocytes,
and induces phosphoinositide hydrolysis in RL12-NP cells.
In addition, OT- and VP-induced phosphorylation of focal
adhesion kinases in pre-T cells could promote the
establishment of immune dsynapsesT between very imma-
ture pre-T cells and thymic stromal cells (Martens and
Geenen, 2000). Such morphological units are of crucial
importance for the implementation of the T-cell differ-
entiation program.
The other objective of this study was to investigate the
functional importance of the thymic OT/VP-mediated signal-
ing on parameters of T-cell differentiation and survival.
FTOC is an appropriate model to study in vitro T-cell
differentiation since FTOC conserve spatial interactions
between differentiating T cells and thymic stromal cells
(Jenkinson and Anderson, 1994). In this model, immature
thymic T cells proliferate and differentiate whereas isolated
thymocytes quickly die in vitro. OT and VP transcription in
murine FTOC was confirmed by RT-PCR followed by
Southern blotting with specific OT and VP oligonucleotides.
The expression of both genes was maintained during the 7-
day culture. After 7-day FTOC, the V1bR antagonist SSR
149451 decreased the early differentiation from DN to DP
stage, while it favored CD8+ commitment. SSR 149451
induced only a little decrease in DN T cell early apoptosis. It
will be interesting to investigate the CD4+/CD8+ balance in
the recent V1bR/ mice (Tanoue et al., 2004) so to see
whether an increase appears in the percentage of thymic
CD8+ T cells. The OTR antagonist increased apoptosis of
CD8+ T cells in this experiment, in accordance with the OT-
I. Hansenne et al. / Journal of Neuroimmunology 158 (2005) 67–7574mediated mitogenic properties evidenced in a previous study
(Martens et al., 1992).
A number of studies are currently revealing the
importance for the establishment of central T-cell self-
tolerance resulting from the intrathymic expression of genes
encoding neuroendocrine and peripheral tissue-specific
antigens. Our findings show that the neuroendocrine
precursors encoded by those genes also control T-cell
differentiation after binding to neuroendocrine receptors
expressed by pre-T cells. This supports the model of a dual
role for thymic neuroendocrine precursors according to their
behavior either as the source of self-antigens in T-cell
negative selection, or as accessory signals for the develop-
ment/survival of self-tolerant T cells (Martens et al., 1996a).
With regard to OT and VP transcription in the thymus, our
studies until now provide evidence that thymic OT, besides
its role as the tolerogenic self-antigen of this family, can also
bind to OTR expressed by all thymic T-cell subsets and
phosphorylate focal adhesion kinases thereby promoting the
formation of immune dsynapsesT between TEC and early
immature T-cells. Furthermore, thymic OT and VP can bind
to V1bR on DP and CD8+ thymic T cells, thereby
facilitating the DN–DP transition during T-cell differentia-
tion, and regulating the final balance between mature CD4+
and CD8+ thymic T lymphocytes.Acknowledgements
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